(NewsUSA) - Those who suffer from eye infections that threaten a person’s vision have a new treatment option that is noninvasive and counters the problem of antibiotic resistance, based on recent research and clinical work.

Many eye infections are caused by multi-drug-resistant strains of bacteria and other pathogens, and standard treatments are limited, according to investigators at the Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine in Florida.

VisiRose, a newly launched, privately-held clinical-stage biotechnology company affiliated with Provectus Biopharmaceuticals (OTCQB: PVCT), is collaborating with Bascom Palmer to commercialize a novel, noninvasive therapy for severe eye infections. The treatment, known as Rose Bengal Photodynamic Antimicrobial Therapy (RB-PDAT), combines a bioactive synthetic small molecule known as Rose Bengal Sodium with a light-based medical device to help manage eye infections caused by bacteria, fungi, and parasites.

“RB-PDAT represents a consequential solution for patients at risk of vision loss from severe infectious keratitis,” said Dominic Rodrigues, acting CEO of VisiRose. RB-PDAT treatment has been associated with rapid resolution of severe eye infections and improved vision outcomes for patients in clinical studies in the U.S., India, Brazil, and Mexico, according to the company.

“We believe Bascom Palmer’s innovative therapy combines infection-fighting capabilities with vision-preserving benefits, paving the way for a brighter future for those struggling with this challenging condition,” said Rodrigues, who also serves as vice chairman of the board of directors and president of Provectus.

Rose Bengal Sodium, the company’s flagship molecule, has demonstrated effectiveness against multi-drug-resistant Pseudomonas aeruginosa, among other strains, in a laboratory setting. At the Ocular Microbiology and Immunology Group conference in 2023, Bascom Palmer researchers reported that 76% of the first 100 patients treated with RB-PDAT at Bascom Palmer, who had severe eye infections unresponsive to standard treatment,achieved successful vision outcomes, with an average time to resolution of just over 6 months.

In a case series published last year in the medical journal JAMA Ophthalmology of nine adults who experienced severe eye infections caused by contaminated artificial tears, RB-PDAT was effective as an addition to antibiotics and helped improve vision outcomes in two patients who received this new therapy, according to Bascom Palmer researchers: a man in his 40s who came to the emergency department with severe pain and decreased vision in his left eye; and a woman in her 80s with worsening redness and visual loss in her right eye.

“This innovative therapy leverages the power of the versatile rose bengal small molecule to fight infection and offers new hope for preserving vision," Rodrigues said.

RB-PDAT has shown promising results in treating severe eye infections in more than 500 individuals worldwide where standard therapies have failed, according to the company press release. Notably, patients in India and Brazil were treated much earlier with RB-PDAT, receiving the oculat treatment as first-line therapy. “VisiRose has the potential to help fill a critical treatment gap in global eye care, particularly in regions and populations severely impacted by antimicrobial resistance with limited access to medical solutions,” Ed Pershing added, who is chairman of VisiRose’s board of directors and also serves as CEO and chairman of Provectus’s board.

Visit www.visirose.com to learn more.

Image caption: Juan Carlos Navia, M.D. at Bascom Palmer Eye Institute at the University of Miami Miller School of Medicine, delivering the VisiRose RB PDAT treatment in the clinic.

(NewsUSA) - Every 2 seconds, someone in the United States needs blood, and a single donation can save lives. Shortages in the nation’s blood supply can happen any time. Donors, especially those who donate regularly, keep our blood supply stable.

Blood transfusions are essential for some patients undergoing surgery, or who’ve had serious injuries or are dealing with certain medical conditions. While everyone is impacted when there are shortages of blood and blood products, people living in communities with higher numbers of patients with rare blood types or diseases are disproportionately affected.      

Take those with sickle cell disease (SCD), a condition that affects more than 100,000 people in the U.S., the majority of who are Black or of African ancestry. Many people with SCD need blood transfusions throughout their lives but often find it difficult to get the type they need. That’s why Black or African American blood donors are so vital, as 1 in 3 are a match for people with SCD.

While it may seem outdated to think of blood in terms of race – the practice of segregating donated blood by race was discontinued shortly after World War II – scientific studies have found that, to reduce the risk of transfusion complications, some people do require blood or blood products from donors with the same racial or ethnic background.

Most people can give blood, but only 3% of Americans donate each year. If you are in good health, at least 16 or 17 years old (depending on the state), and weigh at least 110 pounds, consider donating. A diverse blood supply ensures that every American has equitable access to blood and blood products. You can make a difference in your community by donating blood and by encouraging others to do the same.

Learn more by visiting the National Heart, Lung, and Blood Institute’s Blood Diseases & Disorders Education Program.

Callout:

Diversity in Blood Types

Most blood types fall into one of the four major groups: A, B, AB, O. Blood donations from all types are always needed. However, some people have rare blood types. Some of the rare blood types for African Americans include U- and Fy (a-b-). For these patients, the U.S. blood supply must be more diverse. The best blood type match for patients with rare blood types often comes from donors of the same race or similar ethnicity.

(NewsUSA) - Cada 2 segundos, alguna persona en los Estados Unidos necesita sangre.  Una sola donación puede salvar vidas. En cualquier momento se puede presentar escasez en el suministro de sangre del país.

Los donantes, especialmente aquellos que donan regularmente, mantienen estable nuestro suministro de sangre. Las transfusiones de sangre son fundamentales para algunos pacientes que se someten a cirugías, han sufrido lesiones graves o padecen ciertas afecciones médicas. Si bien todos nos vemos afectados cuando hay escasez de sangre y productos sanguíneos, las personas que viven en comunidades con una mayor cantidad de pacientes con enfermedades o tipos de sangre poco comunes se ven afectadas de una manera desproporcionada.

Tomemos como ejemplo a las personas con enfermedad de células falciformes (SCD, por su sigla en inglés), una afección que afecta a más de 100,000 personas en los Estados Unidos, la mayoría de las cuales son de raza negra o de ascendencia Africana. Muchas personas con enfermedad de células falciformes necesitan transfusiones de sangre a lo largo de sus vidas, pero a menudo les resulta difícil obtener el tipo que necesitan. Es por eso que los donantes de sangre afroestadounidenses son tan importantes, ya que uno de cada tres es compatible con las personas con enfermedad de células falciformes.

Si bien puede parecer anticuado pensar en la sangre en términos de raza (la práctica de segregar la sangre donada por raza se suspendió poco después de la Segunda Guerra Mundial), los estudios científicos han descubierto que, para reducir el riesgo de complicaciones en las transfusiones, algunas personas requieren sangre o productos sanguíneos de donantes con el mismo origen racial o étnico.

La mayoría de las personas puede donar sangre, pero sólo el 3% de los estadounidenses dona cada año. Si tiene buena salud, al menos 16 o 17 años (dependiendo del estado) y pesa mínimo 110 libras, considere donar. Un suministro de sangre diverso garantiza que todas las personas en los Estados Unidos tengan acceso equitativo a la sangre y a los productos sanguíneos.

Usted puede marcar la diferencia en su comunidad donando sangre y animando a otros a hacer lo mismo.

Obtenga más información visitando el sitio web del Programa de educación sobre enfermedades y trastornos de la sangre (en inglés), del Instituto Nacional del Corazón, los Pulmones y la Sangre.

Callout:

Diversidad de tipos de sangre La mayoría de los tipos de sangre pertenecen a uno de los cuatro grupos principales: A, B, AB y O. Siempre se necesitan donaciones de sangre de todos los tipos. Sin embargo, algunas personas tienen tipos de sangre poco comunes. Algunos de los tipos de sangre poco comunes entre los afroestadounidenses incluyen U- y Fy (a-b-). Para estos pacientes, el suministro de sangre en los Estados Unidos debe ser más diverso. La mejor compatibilidad del tipo de sangre para los pacientes con tipos de sangre poco comunes suele venir de donantes de la misma raza o grupo ético similar.

(NewsUSA)

(NewsUSA)

(NewsUSA)

(NewsUSA)

(NewsUSA)

(NewsUSA)

(NewsUSA)